METAVIA INC. Research and Development Asset Acquired Other than Through Business Combination, Written-off
METAVIA INC. (MTVA) reported Research and Development Asset Acquired Other than Through Business Combination, Written-off of $8.21 million for the 12-month period ending 2022-12-31, per its 10-K filed 2024-03-28.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff · last filed 2024-03-28
- METAVIA INC. research and development asset acquired other than through business combination, written-off for the quarter ending 2015-03-31 was $908.00K.
- METAVIA INC. research and development asset acquired other than through business combination, written-off for fiscal 2022 was $8.21M.
- METAVIA INC. research and development asset acquired other than through business combination, written-off for fiscal 2020 was $17.34M, a 42.70% increase from fiscal 2019.
- METAVIA INC. research and development asset acquired other than through business combination, written-off for fiscal 2019 was $12.15M, a 37.84% increase from fiscal 2018.
- METAVIA INC. research and development asset acquired other than through business combination, written-off for fiscal 2018 was $8.81M.
| Period end | Research and Development Asset Acquired Other than Through Business Combination, Written-off 3 month | Research and Development Asset Acquired Other than Through Business Combination, Written-off 12 month |
|---|---|---|
| 2022-12-31 | $8.21M 10-K · filed 2024-03-28 | |
| 2020-12-31 | $17.34M 10-K · filed 2022-03-31 | |
| 2019-12-31 | $12.15M 10-K · filed 2021-04-15 | |
| 2018-12-31 | $8.81M 10-K · filed 2020-03-30 | |
| 2015-12-31 | $908.00K 10-K · filed 2018-03-20 | |
| 2015-03-31 | $908.00K 10-K · filed 2017-03-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| Theriva Biologics, Inc. (TOVX) | United States | $0.011B | |
| Azitra, Inc. (AZTR) | United States | $0.010B | -0.81 |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| Medicus Pharma Ltd. (MDCX) | $0.010B | ||
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| Aprea Therapeutics, Inc. (APRE) | United States | $0.010B | -0.78 |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |